Apolipoprotein B (ApoB)

Apolipoprotein B (ApoB) is a protein that sits on the surface of cholesterol-carrying particles that can contribute to plaque buildup in arteries. It’s found on LDL (“bad cholesterol”), VLDL, and other atherogenic lipoproteins. Think of ApoB like a “barcode” that labels each potentially harmful cholesterol particle in your bloodstream. Importantly, each of these particles carries one ApoB molecule, so your ApoB result reflects the number of cholesterol particles that can interact with blood vessel walls—not just how much cholesterol is inside them.

This matters because traditional cholesterol tests (like LDL-cholesterol) mainly measure the amount of cholesterol carried inside particles. But two people can have the same LDL-cholesterol level and very different particle counts: one may have fewer, larger particles, while another may have many more small particles carrying less cholesterol each. Even if each particle carries less cholesterol, a high number of particles means more chances for particles to enter artery walls and drive plaque formation. ApoB is also practical because it is not significantly affected by whether you fast before the test, and it can help clinicians identify inherited lipid disorders or “hidden risk” patterns that may be missed by standard lipid panels.

ApoB is strongly linked to long-term cardiovascular risk because atherosclerosis (plaque buildup) is driven by the number of atherogenic particles circulating over time. When ApoB is high, it means there are more cholesterol particles capable of penetrating the artery wall. Once particles become trapped in the vessel lining, they can trigger inflammation and plaque development, which narrows arteries and increases the risk of heart attack, stroke, and other vascular disease.

Multiple studies and expert groups—including the National Lipid Association—highlight that ApoB often predicts cardiovascular risk more accurately than LDL-cholesterol, especially in people with higher triglycerides, obesity, diabetes, or mixed lipid patterns. This is because LDL-cholesterol can look “normal” even when ApoB is elevated: the cholesterol content per particle may be lower, but the particle count can still be high. In other words, a person may appear low-risk on a standard cholesterol panel while still carrying a high burden of ApoB-containing particles that drive atherosclerosis.

ApoB is also valuable for earlier prevention. Cardiovascular disease develops over decades, and ApoB helps detect risk earlier—particularly in younger adults and those with a family history of early heart disease. In addition, newer research suggests that “excess ApoB” (more ApoB than would be expected for a given LDL-cholesterol) is a meaningful warning sign of hidden particle-driven risk in both women and men.

Lowering ApoB through healthy habits is a foundational prevention strategy. In higher-risk settings, ApoB is also used to help guide treatment decisions and monitor whether risk is truly improving. The clinical message is simple: the fewer ApoB-containing particles circulating long-term, the lower the lifetime exposure of arteries to plaque-forming particles, and the lower the risk of future cardiovascular events.

ApoB levels reflect how your body packages, transports, and clears fats. They rise with insulin resistance, inflammation, and poor lipid metabolism.

Common factors influencing ApoB include:

• High intake of sugar and refined starches – raises triglycerides and promotes small, dense LDL particles.

• Saturated fat intake – may raise ApoB in some individuals, depending on genetics and metabolic status.

• Insulin resistance and type 2 diabetes – increase production of ApoB-containing particles.

• Hypothyroidism – slows cholesterol clearance and raises ApoB.

• Obesity and visceral fat – elevate ApoB through increased liver fat and inflammation.

• Chronic stress or poor sleep – impair lipid metabolism and drive inflammatory pathways.

• Smoking and alcohol abuse – worsen oxidative stress and particle oxidation.

• Genetic variants (ApoB mutations) – can cause persistently high ApoB independent of lifestyle.

If your results are high

Your results are high, meaning you have an increased number of cholesterol particles that can contribute to plaque buildup.

1. Optimise your nutrition

• Reduce refined carbohydrates, sugar, and ultra-processed foods.

• Emphasise whole, unprocessed foods, rich in fibre, colourful vegetables, lean proteins, and healthy fats (olive oil, nuts, seeds, oily fish).

• Replace saturated fats (butter, fatty meats, coconut oil) with unsaturated fats when ApoB is high.

• Increase soluble fibre (oats, psyllium, beans, flaxseeds) to reduce LDL particle number and ApoB.
  

2. Improve insulin sensitivity

• Exercise regularly: combine aerobic training and resistance work to improve lipid clearance.

• Manage stress and prioritise 7–9 hours of sleep per night.

• Moderate alcohol; excess intake increases triglycerides and ApoB.
  

3. Support thyroid and liver function

• Check thyroid health if ApoB is persistently high.

• Limit alcohol and support liver detoxification with cruciferous vegetables, leafy greens, and hydration.

4. Quit smoking

• Smoking drives oxidative stress, making ApoB particles more likely to become plaque-forming.

Goal range:< 80 mg/dL, ideally< 65 mg/dL

1. Wilson PWF, Jacobson TA, Martin SS, et al. Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations—A Scientific Statement From the National Lipid Association Writing Group. Journal of Clinical Lipidology. 2021;15(5):629–648. doi:10.1016/j.jacl.2021.09.046.

2. Galimberti F, Casula M, Olmastroni E. Apolipoprotein B Compared With LDL Cholesterol in ASCVD Risk Assessment. Pharmacological Research. 2023;195:106873. doi:10.1016/j.phrs.2023.106873.

3. Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess ApoB and Cardiovascular Risk in Women and Men. Journal of the American College of Cardiology. 2024;83(23):2262–2273. doi:10.1016/j.jacc.2024.03.423.

4. Stone NJ, Smith SC, Orringer CE, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022;79(8):819–836. doi:10.1016/j.jacc.2021.12.016.

5. De Oliveira-Gomes D, Joshi PH, Peterson ED, et al. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150(1):62–79. doi:10.1161/CIRCULATIONAHA.124.068885.